US Supreme Court Contemplating Whether to Review a Lower Court Ruling on Illumina’s Fetal DNA Testing Patents
shot by IP News Shots / 7:02 pm on 01 March, 2021
A US Supreme Court case regarding Illumina Inc.’s fetal DNA test patents will allow the justices to solidify a road map on how the biotechnology companies can secure their diagnostic inventions. Notably, the high court will have to take a call on whether to review a US Court of Appeals for the Federal Circuit (CAFC) ruling on the said patents. If the CAFC’s decision stays, it will provide a playbook for saving diagnostic patents.
Read more at: https://news.bloomberglaw.com/ip-law/high-court-mulls-taking-up-diagnostic-patent-eligibility-fight
Industry: Biotechnology
BGI to Approach COA against Illumina
shot by IP News Shots / 7:38 pm on 26 February, 2021
The BGI Group has attained permission to appeal to the Court of Appeals against a high court ruling in favour of Illumina Inc. The high court ruling had found a BGI subsidiary MGI Tech Co., Ltd. infringing on four out of five asserted patents belonging to Illumina, which are related to DNA sequencing technology.
Read More at: https://www.lifesciencesipreview.com/news/bgi-secures-appeal-trial-over-illumina-dna-verdict-4378
Industry: Biotechnology
Illumina Wants Patent Lawsuit to Take Precedence Over Antitrust Suit
shot by IP News Shots / 7:05 pm on 24 February, 2021
The US District Court for the Northern District of California has been urged by Illumina Inc. to halt an antitrust case brought by Complete Genomics Incorporated (CGI). Illumina has presented the request so it can first pursue a patent infringement case that it brought against CGI as a result of which the latter filed the antitrust suit. Illumina had accused CGI of infringing on their DNA sequencing patents with a lawsuit.
Read More at: https://www.law360.com/lifesciences/articles/1357548/illumina-wants-entirely-derivative-antitrust-suit-paused
Industry: Biotechnology
ERS Genomics Enters into a Licensing Agreement with G+FLAS
shot by IP News Shots / 6:57 pm on 24 February, 2021
ERS Genomics Limited has announced the signing of a non-exclusive licensing agreement with G+FLAS Life Sciences for the former’s CRISPR-Cas9 patent portfolio. The financial terms of the agreement have not been divulged.
Industry: Biotechnology
MindMed to Acquire HealthMode’s IP and Clinical Trial Platforms
shot by IP News Shots / 6:49 pm on 19 February, 2021
Mind Medicine Inc. (MindMed) has entered into an acquisition deal and is all set to acquire the intellectual property and other assets of HealthMode, Inc. As per the financial details of the deal, MindMed will pay CAD $300,000 in cash in addition to multiple voting shares.
Read More at: https://aithority.com/technology/life-sciences/mindmed-reaches-agreement-to-acquire-healthmode/
Industry: Biotechnology, Healthcare Technology
Fluidigm Accepts Defeat in Patent Suit against IONpath
shot by IP News Shots / 7:29 pm on 18 February, 2021
Fluidigm Corp. has accepted defeat in a patent infringement case that it filed against IONpath Inc. at the US District Court for the Northern District of California. Fluidigm gave up their allegation of patent infringement after the Northern California court’s interpretation of a key term in two patents inferring that IONpath did not infringe on the asserted patents.
Read More at: https://news.bloomberglaw.com/pharma-and-life-sciences/fluidigm-takes-a-loss-in-patent-suit-after-showdown-defeat
Industry: Biotechnology